PF-Atlas › Clinical Trials › NCT00903201
28 Day Repeat Dose in Cystic Fibrosis Patients
SB656933 · Phase 2
Registry ID
NCT00903201
Phase
Phase 2
Status
Completed
Drug / intervention
SB656933
Sponsor
GlaxoSmithKline
Start
2009-09-28
About this trial
SB656933 is evaluated in NCT00903201, a Phase 2 idiopathic pulmonary fibrosis study sponsored by GlaxoSmithKline. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00903201 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.